Both announcements are but fluff. Simple facts tell the whole story. The only thing that is intriguing is why the con note last Friday when there were straight up placements before and after
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%